Integrated BioPharma appoints new CEO
This article was originally published in Scrip
Integrated BioPharma (US) has appointed Jeffrey Leach to succeed Gerald Kay as chief executive officer and president. Mr Leach also was appointed by the board as a director to fill the vacancy created by the death of Zarko Kraljevic in March 2008. Before joining the company in 2006, Mr Leach was a general partner in The Stone Pine Companies.
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.